Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008)

Official Title

A Phase 2, Multicentre, Multi Arm, Study to Evaluate MK-1308A (Co-formulated Quavonlimab (MK-1308)/Pembrolizumab) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer: (MK-1308A-008)

Summary:

The purpose of this study is to assess the efficacy and safety of co-formulated pembrolizumab/quavonlimab versus other treatments in participants with MSI-H or dMMR Metastatic Stage IV Colorectal Cancer.

Trial Description

Primary Outcome:

  • Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR)
Secondary Outcome:
  • Duration of Response (DOR) per RECIST 1.1 as assessed by BICR
  • Progression-Free Survival (PFS) per RECIST 1.1 as assessed by BICR
  • PFS per RECIST 1.1 as assessed by Investigator
  • ORR per RECIST 1.1 as assessed by Investigator
  • DOR per RECIST 1.1 as assessed by Investigator
  • Overall Survival (OS)
  • Number of Participants Who Experienced an Adverse Event (AE)
  • Number of Participants Discontinuing Study Treatment Due to an AE

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society